BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26773212)

  • 1. MicroRNAs: Non-coding fine tuners of receptor tyrosine kinase signalling in cancer.
    Donzelli S; Cioce M; Muti P; Strano S; Yarden Y; Blandino G
    Semin Cell Dev Biol; 2016 Feb; 50():133-42. PubMed ID: 26773212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.
    Abou-Fayçal C; Hatat AS; Gazzeri S; Eymin B
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma.
    Mataki H; Seki N; Chiyomaru T; Enokida H; Goto Y; Kumamoto T; Machida K; Mizuno K; Nakagawa M; Inoue H
    Int J Oncol; 2015 Mar; 46(3):1039-50. PubMed ID: 25522678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
    Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring interactions between receptor tyrosine kinases and their downstream effector proteins in living cells using bioluminescence resonance energy transfer.
    Tan PK; Wang J; Littler PL; Wong KK; Sweetnam TA; Keefe W; Nash NR; Reding EC; Piu F; Brann MR; Schiffer HH
    Mol Pharmacol; 2007 Dec; 72(6):1440-6. PubMed ID: 17715395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA regulation of growth factor receptor signaling in human cancer cells.
    Giles KM; Barker A; Zhang PM; Epis MR; Leedman PJ
    Methods Mol Biol; 2011; 676():147-63. PubMed ID: 20931396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNAs as the fine-tuners of Src oncogenic signalling.
    Oneyama C; Okada M
    J Biochem; 2015 Jun; 157(6):431-8. PubMed ID: 25862810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of epidermal growth factor receptor induces sequestration of extracellular signal-related kinases and selective attenuation of specific epidermal growth factor-mediated signal transduction pathways.
    Habib AA; Chun SJ; Neel BG; Vartanian T
    Mol Cancer Res; 2003 Jan; 1(3):219-33. PubMed ID: 12556561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases.
    Abella JV; Park M
    Am J Physiol Endocrinol Metab; 2009 May; 296(5):E973-84. PubMed ID: 19240253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission.
    Gschwind A; Zwick E; Prenzel N; Leserer M; Ullrich A
    Oncogene; 2001 Mar; 20(13):1594-600. PubMed ID: 11313906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor.
    Liu L; Shao X; Gao W; Zhang Z; Liu P; Wang R; Huang P; Yin Y; Shu Y
    FEBS J; 2012 Oct; 279(20):3800-12. PubMed ID: 22883469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
    Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
    Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-modulated autophagic signaling networks in cancer.
    Fu LL; Wen X; Bao JK; Liu B
    Int J Biochem Cell Biol; 2012 May; 44(5):733-6. PubMed ID: 22342941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphoproteomic studies of receptor tyrosine kinases: future perspectives.
    Huang PH
    Mol Biosyst; 2012 Apr; 8(4):1100-7. PubMed ID: 22134727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-Pulse Endosomal Stimulation of Receptor Tyrosine Kinases Induces Cell Proliferation.
    Pennock S; Billing S; Wang Z; Wang Y
    Methods Mol Biol; 2017; 1652():127-133. PubMed ID: 28791639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression.
    Ahmad N; Gali H; Javed S; Agarwal R
    Biochem Biophys Res Commun; 1998 Jun; 247(2):294-301. PubMed ID: 9642119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis.
    Templeton AJ; Diez-Gonzalez L; Ace O; Vera-Badillo F; Seruga B; Jordán J; Amir E; Pandiella A; Ocaña A
    Cancer Treat Rev; 2014 Oct; 40(9):1048-55. PubMed ID: 25217796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of the MIR155 host gene in physiological and pathological processes.
    Elton TS; Selemon H; Elton SM; Parinandi NL
    Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The epidermal growth factor receptor (EGFR) and proline rich tyrosine kinase 2 (PYK2) are involved in tissue factor dependent factor VIIa signalling in HaCaT cells.
    Wiiger MT; Prydz H
    Thromb Haemost; 2004 Jul; 92(1):13-22. PubMed ID: 15213840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.